Improving combination cancer therapy: the CombiPlex ® development platform
Current combination therapy approaches assume that better outcomes are achieved by combining drugs at their maximally tolerated doses. However, administration of individual agents cannot consistently deliver synergistic drug ratios to tumor cells due to differences in pharmacokinetics of the individ...
Gespeichert in:
| Veröffentlicht in: | Future oncology (London, England) England), 2018-06, Vol.14 (13), p.1317-1332 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1332 |
|---|---|
| container_issue | 13 |
| container_start_page | 1317 |
| container_title | Future oncology (London, England) |
| container_volume | 14 |
| creator | Tolcher, Anthony W Mayer, Lawrence D |
| description | Current combination therapy approaches assume that better outcomes are achieved by combining drugs at their maximally tolerated doses. However, administration of individual agents cannot consistently deliver synergistic drug ratios to tumor cells due to differences in pharmacokinetics of the individual drugs. Further, the toxicity of combination regimens often necessitates administration of suboptimal dosages. Delivery technologies, such as the CombiPlex
platform, can enable efficient and sustained delivery of combination treatments at a synergistic ratio. The CombiPlex platform determines synergistic drug ratios in vitro and identifies an appropriate nanoscale carrier to maintain that ratio in vivo and enhance its delivery to tumor cells. CPX-351, a dual-drug liposomal encapsulation of cytarabine and daunorubicin, is the first clinical proof-of-concept example of the CombiPlex platform. |
| doi_str_mv | 10.2217/fon-2017-0607 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2275941347</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2275941347</sourcerecordid><originalsourceid>FETCH-LOGICAL-c360t-c54d0857d121217ed155a2c1a7c2e70d39be2b05ca32bccfb2e34b492e55a2073</originalsourceid><addsrcrecordid>eNo9kMtOwzAQRS0EoqWwZIsssTb4lbhmhyoeFZVgAWvLcSaQKrGDk1T0p_gIvoxELWgWM9Ic3RkdhM4ZveKcqesieMIpU4SmVB2gKVNSkrmg7HCYpdIkTbWcoJO2XVMqlUjoMZpwLVKhtZyip2XdxLAp_Tt2oc5Kb7syeOysdxBx9wHRNtubccCLcf9SwRf--cY5bKAKTQ2-w01luyLE-hQdFbZq4WzfZ-jt_u518UhWzw_Lxe2KOJHSjrhE5nSeqJzxoRTkLEksd8wqx0HRXOgMeEYTZwXPnCsyDkJmUnMYOarEDF3ucofPP3toO7MOffTDScO5SrRkQo4U2VEuhraNUJgmlrWNW8OoGdWZQZ0Z1ZlR3cBf7FP7rIb8n_5zJX4BT1pqhQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2275941347</pqid></control><display><type>article</type><title>Improving combination cancer therapy: the CombiPlex ® development platform</title><source>MEDLINE</source><source>PubMed Central</source><creator>Tolcher, Anthony W ; Mayer, Lawrence D</creator><creatorcontrib>Tolcher, Anthony W ; Mayer, Lawrence D</creatorcontrib><description>Current combination therapy approaches assume that better outcomes are achieved by combining drugs at their maximally tolerated doses. However, administration of individual agents cannot consistently deliver synergistic drug ratios to tumor cells due to differences in pharmacokinetics of the individual drugs. Further, the toxicity of combination regimens often necessitates administration of suboptimal dosages. Delivery technologies, such as the CombiPlex
platform, can enable efficient and sustained delivery of combination treatments at a synergistic ratio. The CombiPlex platform determines synergistic drug ratios in vitro and identifies an appropriate nanoscale carrier to maintain that ratio in vivo and enhance its delivery to tumor cells. CPX-351, a dual-drug liposomal encapsulation of cytarabine and daunorubicin, is the first clinical proof-of-concept example of the CombiPlex platform.</description><identifier>ISSN: 1479-6694</identifier><identifier>EISSN: 1744-8301</identifier><identifier>DOI: 10.2217/fon-2017-0607</identifier><identifier>PMID: 29363994</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>Animals ; Antineoplastic Combined Chemotherapy Protocols - pharmacology ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biomedical Technology - methods ; Cancer therapies ; Chemotherapy ; Clinical trials ; Constituents ; Cytotoxicity ; Dose-Response Relationship, Drug ; Drug Compounding - methods ; Drug Delivery Systems - methods ; Drug dosages ; Drug Synergism ; Humans ; Leukemia ; Liposomes ; Mutation ; Nanoparticles ; Neoplasms - drug therapy ; Ratios ; Schedules ; Studies ; Treatment Outcome</subject><ispartof>Future oncology (London, England), 2018-06, Vol.14 (13), p.1317-1332</ispartof><rights>2018. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c360t-c54d0857d121217ed155a2c1a7c2e70d39be2b05ca32bccfb2e34b492e55a2073</citedby><cites>FETCH-LOGICAL-c360t-c54d0857d121217ed155a2c1a7c2e70d39be2b05ca32bccfb2e34b492e55a2073</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29363994$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tolcher, Anthony W</creatorcontrib><creatorcontrib>Mayer, Lawrence D</creatorcontrib><title>Improving combination cancer therapy: the CombiPlex ® development platform</title><title>Future oncology (London, England)</title><addtitle>Future Oncol</addtitle><description>Current combination therapy approaches assume that better outcomes are achieved by combining drugs at their maximally tolerated doses. However, administration of individual agents cannot consistently deliver synergistic drug ratios to tumor cells due to differences in pharmacokinetics of the individual drugs. Further, the toxicity of combination regimens often necessitates administration of suboptimal dosages. Delivery technologies, such as the CombiPlex
platform, can enable efficient and sustained delivery of combination treatments at a synergistic ratio. The CombiPlex platform determines synergistic drug ratios in vitro and identifies an appropriate nanoscale carrier to maintain that ratio in vivo and enhance its delivery to tumor cells. CPX-351, a dual-drug liposomal encapsulation of cytarabine and daunorubicin, is the first clinical proof-of-concept example of the CombiPlex platform.</description><subject>Animals</subject><subject>Antineoplastic Combined Chemotherapy Protocols - pharmacology</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biomedical Technology - methods</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Constituents</subject><subject>Cytotoxicity</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Compounding - methods</subject><subject>Drug Delivery Systems - methods</subject><subject>Drug dosages</subject><subject>Drug Synergism</subject><subject>Humans</subject><subject>Leukemia</subject><subject>Liposomes</subject><subject>Mutation</subject><subject>Nanoparticles</subject><subject>Neoplasms - drug therapy</subject><subject>Ratios</subject><subject>Schedules</subject><subject>Studies</subject><subject>Treatment Outcome</subject><issn>1479-6694</issn><issn>1744-8301</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNo9kMtOwzAQRS0EoqWwZIsssTb4lbhmhyoeFZVgAWvLcSaQKrGDk1T0p_gIvoxELWgWM9Ic3RkdhM4ZveKcqesieMIpU4SmVB2gKVNSkrmg7HCYpdIkTbWcoJO2XVMqlUjoMZpwLVKhtZyip2XdxLAp_Tt2oc5Kb7syeOysdxBx9wHRNtubccCLcf9SwRf--cY5bKAKTQ2-w01luyLE-hQdFbZq4WzfZ-jt_u518UhWzw_Lxe2KOJHSjrhE5nSeqJzxoRTkLEksd8wqx0HRXOgMeEYTZwXPnCsyDkJmUnMYOarEDF3ucofPP3toO7MOffTDScO5SrRkQo4U2VEuhraNUJgmlrWNW8OoGdWZQZ0Z1ZlR3cBf7FP7rIb8n_5zJX4BT1pqhQ</recordid><startdate>20180601</startdate><enddate>20180601</enddate><creator>Tolcher, Anthony W</creator><creator>Mayer, Lawrence D</creator><general>Future Medicine Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>EHMNL</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20180601</creationdate><title>Improving combination cancer therapy: the CombiPlex ® development platform</title><author>Tolcher, Anthony W ; Mayer, Lawrence D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c360t-c54d0857d121217ed155a2c1a7c2e70d39be2b05ca32bccfb2e34b492e55a2073</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Animals</topic><topic>Antineoplastic Combined Chemotherapy Protocols - pharmacology</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biomedical Technology - methods</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Constituents</topic><topic>Cytotoxicity</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Compounding - methods</topic><topic>Drug Delivery Systems - methods</topic><topic>Drug dosages</topic><topic>Drug Synergism</topic><topic>Humans</topic><topic>Leukemia</topic><topic>Liposomes</topic><topic>Mutation</topic><topic>Nanoparticles</topic><topic>Neoplasms - drug therapy</topic><topic>Ratios</topic><topic>Schedules</topic><topic>Studies</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tolcher, Anthony W</creatorcontrib><creatorcontrib>Mayer, Lawrence D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>UK & Ireland Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Future oncology (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tolcher, Anthony W</au><au>Mayer, Lawrence D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Improving combination cancer therapy: the CombiPlex ® development platform</atitle><jtitle>Future oncology (London, England)</jtitle><addtitle>Future Oncol</addtitle><date>2018-06-01</date><risdate>2018</risdate><volume>14</volume><issue>13</issue><spage>1317</spage><epage>1332</epage><pages>1317-1332</pages><issn>1479-6694</issn><eissn>1744-8301</eissn><abstract>Current combination therapy approaches assume that better outcomes are achieved by combining drugs at their maximally tolerated doses. However, administration of individual agents cannot consistently deliver synergistic drug ratios to tumor cells due to differences in pharmacokinetics of the individual drugs. Further, the toxicity of combination regimens often necessitates administration of suboptimal dosages. Delivery technologies, such as the CombiPlex
platform, can enable efficient and sustained delivery of combination treatments at a synergistic ratio. The CombiPlex platform determines synergistic drug ratios in vitro and identifies an appropriate nanoscale carrier to maintain that ratio in vivo and enhance its delivery to tumor cells. CPX-351, a dual-drug liposomal encapsulation of cytarabine and daunorubicin, is the first clinical proof-of-concept example of the CombiPlex platform.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>29363994</pmid><doi>10.2217/fon-2017-0607</doi><tpages>16</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1479-6694 |
| ispartof | Future oncology (London, England), 2018-06, Vol.14 (13), p.1317-1332 |
| issn | 1479-6694 1744-8301 |
| language | eng |
| recordid | cdi_proquest_journals_2275941347 |
| source | MEDLINE; PubMed Central |
| subjects | Animals Antineoplastic Combined Chemotherapy Protocols - pharmacology Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomedical Technology - methods Cancer therapies Chemotherapy Clinical trials Constituents Cytotoxicity Dose-Response Relationship, Drug Drug Compounding - methods Drug Delivery Systems - methods Drug dosages Drug Synergism Humans Leukemia Liposomes Mutation Nanoparticles Neoplasms - drug therapy Ratios Schedules Studies Treatment Outcome |
| title | Improving combination cancer therapy: the CombiPlex ® development platform |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T14%3A12%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Improving%20combination%20cancer%20therapy:%20the%20CombiPlex%20%C2%AE%20development%20platform&rft.jtitle=Future%20oncology%20(London,%20England)&rft.au=Tolcher,%20Anthony%20W&rft.date=2018-06-01&rft.volume=14&rft.issue=13&rft.spage=1317&rft.epage=1332&rft.pages=1317-1332&rft.issn=1479-6694&rft.eissn=1744-8301&rft_id=info:doi/10.2217/fon-2017-0607&rft_dat=%3Cproquest_cross%3E2275941347%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2275941347&rft_id=info:pmid/29363994&rfr_iscdi=true |